Genitourinary Drugs Market Size

Genitourinary Drugs Market Size

Genitourinary Drugs Market size was valued at USD 28.7 billion in 2023 growing at a CAGR of 2.3% between 2024 and 2032. The key factors driving the growth of the market include the increasing prevalence of genitourinary disorders, such as urinary tract infections (UTIs). UTIs are among the most common infections in women, and their high incidence rate is driving the demand for effective anti-infective medications, which boosts market growth.

For instance, according to an article published by the National Institutes of Health, it has been reported that between 24% and 45% of women in the U.S. report urinary incontinence. Women between the ages of 20 and 39 experience some degree of incontinence between 7% and 37%, while women over 60 report daily incontinence between 9% and 39%.
 

Additionally, the growing elderly population, particularly in developed countries, leads to a higher prevalence of benign prostatic hyperplasia (BPH), necessitating treatment options like alpha-blockers and hormonal therapies. This trend is anticipated to foster market growth.
 

Genitourinary tract agents are medications used to treat conditions of the reproductive organs and the excretory or urinary tract. They address a range of issues, including reproductive and urinary tract infections, congenital abnormalities, cancers of the urological and reproductive systems, and sexual dysfunction.